Brigatinib

5 trials 1 recruiting LOncology

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

1 Recruiting

4 Completed trials

5 Sponsors

12 Countries

Phase II

Phase I/II

Phase II: 4 Phase I/II: 1

Oversight events:

1 serious breach across 1 trial

View oversight register →

Indications tested

ALK gene rearrangement positive 1 Non-small cell lung cancer stage IV 1 Non-small cell lung cancer stage IIIB 1 Non-small cell lung cancer 1 Inflammatory myofibroblastic tumour 1

Sponsors using this IMP

ETOP IBCSG Partners Foundation 1 Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH 1 Fundacion GECP 1 Intergroupe Francophone De Cancerologie Thoracique 1 Prinses Maxima Centrum voor Kinderoncologie B.V. 1

All trials

5 total

Brigatinib in pediatric and young adult patients with ALK+ ALCL, IMT or other solid tumors (Briga-PED) Recruiting

2024-513412-10-00 Phase I/II 12 countries Prinses Maxima Centrum voor Kinderoncologie B.V.
IFCT-2101 MASTERPROTOCOL ALK : Study of safety and efficacy of brigatinib and carboplatin-pemetrexed combination therapy or brigatinib monot… Ended

2023-510387-13-00 Phase II 1 country Intergroupe Francophone De Cancerologie Thoracique
Utility of analysis in blood of the evolution of the drug brigatinib for patients with lung cancer with ALK mutations Ended

2024-511317-38-00 Phase II 1 country Fundacion GECP
ABP - Advancing Brigatinib Properties in anaplastic lymphoma kinase positive nonsmall cell lung cancer (ALK+ NSCLC) patients by deep phenoty… Ended

2024-513947-94-00 Phase II 1 country Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH
A clinical study for patients with newly diagnosed, locally advanced non-small cell lung cancer (NSCLC) with a change in the ALK-gene, to te… Ended

2022-502467-38-00 Phase II 4 countries ETOP IBCSG Partners Foundation

Showing 1–5 of 5 trials

← All drugs A–Z